Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.

PubMed  Google Scholar 

Urick ME, Bell DW. Clinical actionability of molecular targets in endometrial cancer. Nat Rev Cancer. 2019;19:510–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol. 2015;28:836–44.

Article  CAS  PubMed  Google Scholar 

Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, et al. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017;123:802–13.

Article  CAS  PubMed  Google Scholar 

McAlpine J, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol. 2018;244:538–49.

Article  PubMed  Google Scholar 

Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin Cancer Res. 2016;22:4215–24.

Article  CAS  PubMed  Google Scholar 

de Jonge MM, Auguste A, van Wijk LM, Schouten PC, Meijers M, Ter Haar NT, et al. Frequent homologous recombination deficiency in high-grade endometrial carcinomas. Clin Cancer Res. 2019;25:1087–97.

Article  PubMed  Google Scholar 

Jiang F, Jiang S, Cao D, Mao M, Xiang Y. Immunologic signatures across molecular subtypes and potential biomarkers for sub-stratification in endometrial cancer. Int J Mol Sci. 2023;24:1791.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raffone A, Travaglino A, Massimo M, Carbone L, Guida M, Insabato L, et al. TCGA molecular groups of endometrial cancer: pooled data about prognosis. Gynecol Oncol. 2019;155:374–83.

Article  CAS  PubMed  Google Scholar 

Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D, et al. Endometrial cancer. Nat Rev Dis Prim. 2021;7:88.

Article  PubMed  Google Scholar 

Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018;29:1180–8.

Article  CAS  PubMed  Google Scholar 

Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015;113:299–310.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M. Targeting DNA damage response pathways in cancer. Nat Rev Cancer. 2023;23:78–94.

Article  CAS  PubMed  Google Scholar 

Li W, Gao L, Yi X, Shi S, Huang J, Shi L, et al. Patient assessment and therapy planning based on homologous recombination repair deficiency. Genom Proteom Bioinform. 2023;21:962–75.

Article  CAS  Google Scholar 

Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22:3764–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60:547–60.

Article  PubMed  Google Scholar 

Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med. 2017;23:517–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016;7:13587–98.

Article  PubMed  PubMed Central  Google Scholar 

Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, et al. Genomic and molecular landscape of DNA damage repair deficiency across The Cancer Genome Atlas. Cell Rep. 2018;23:239–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shi Z, Chen B, Han X, Gu W, Liang S, Wu L. Genomic and molecular landscape of homologous recombination deficiency across multiple cancer types. Sci Rep. 2023;13:8899.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beinse G, Just PA, Le Frere Belda MA, Laurent-Puig P, Jacques S, Koual M, et al. Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers. Br J Cancer. 2022;127:1123–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Witz A, Dardare J, Betz M, Michel C, Husson M, Gilson P, et al. Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics. Biomark Res. 2025;13:31.

Article  PubMed  PubMed Central  Google Scholar 

Shen M, Lin Y, Yao Z, Lin L, Sun Y. Homologous recombination deficiency in endometrial cancer: association with clinical and molecular characteristics. ESMO Open. 2024;9:16P.

Article  Google Scholar 

Jamieson A, McAlpine JN. Molecular profiling of endometrial cancer from TCGA to clinical practice. J Natl Compr Cancer Netw. 2023;21:210–6.

Article  CAS  Google Scholar 

Corr BR, Erickson BK, Barber EL, Fisher CM, Slomovitz B. Advances in the management of endometrial cancer. BMJ. 2025;388:e080978.

Article  CAS  PubMed  Google Scholar 

Wang M, Chen X, Dai Y, Wu D, Liu F, Yang Z, et al. Concordance study of a 520-gene next-generation sequencing-based genomic profiling assay of tissue and plasma samples. Mol Diagn Ther. 2022;26:309–22.

Article  PubMed  Google Scholar 

León-Castillo A, Britton Heidi, McConechy MK, McAlpine JN, Nout R, Kommoss S, et al. Interpretation of somatic POLE mutations in endometrial carcinoma. J Pathol. 2020;250:323–35.

Article  PubMed  PubMed Central  Google Scholar 

Zhu L, Huang Y, Fang X, Liu C, Deng W, Zhong C, et al. A novel and reliable method to detect microsatellite instability in colorectal cancer by next-generation sequencing. J Mol Diagn. 2018;20:225–31.

Article  CAS  PubMed  Google Scholar 

Cai Z, Wang Z, Liu C, Shi D, Li D, Zheng M, et al. Detection of microsatellite instability from circulating tumor DNA by targeted deep sequencing. J Mol Diagn. 2020;22:860–70.

Article  CAS  PubMed  Google Scholar 

Jamieson A, de Barros JS, Cochrane DR, Douglas JM, Shankar S, Lynch BJ, et al. Targeted and shallow whole-genome sequencing identifies therapeutic opportunities in p53abn endometrial cancers. Clin Cancer Res. 2024;30:2461–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cohen-Sharir Y, McFarland JM, Abdusamad M, Marquis C, Bernhard SV, Kazachkova M, et al. Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition. Nature. 2021;590:486–91.

Article  CAS